Nebula Research & Development LLC raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 49.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,282 shares of the medical research company's stock after buying an additional 2,415 shares during the quarter. Thermo Fisher Scientific comprises approximately 0.4% of Nebula Research & Development LLC's holdings, making the stock its 14th largest position. Nebula Research & Development LLC's holdings in Thermo Fisher Scientific were worth $3,788,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently modified their holdings of TMO. Norges Bank purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $3,149,754,000. T. Rowe Price Investment Management Inc. boosted its stake in Thermo Fisher Scientific by 86.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock worth $1,604,338,000 after buying an additional 1,433,444 shares during the period. Kovitz Investment Group Partners LLC boosted its stake in Thermo Fisher Scientific by 1,905.4% during the fourth quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after buying an additional 858,193 shares during the period. Proficio Capital Partners LLC boosted its stake in Thermo Fisher Scientific by 68,617.0% during the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock worth $396,810,000 after buying an additional 761,649 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Thermo Fisher Scientific during the fourth quarter worth $377,901,000. 89.23% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research firms have commented on TMO. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research note on Wednesday. UBS Group decreased their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research report on Thursday. StockNews.com downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Friday. Morgan Stanley lifted their target price on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. Finally, Evercore ISI decreased their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research report on Thursday. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus target price of $616.95.
View Our Latest Research Report on Thermo Fisher Scientific
Thermo Fisher Scientific Stock Down 0.6 %
NYSE:TMO traded down $2.69 during midday trading on Monday, reaching $421.55. 2,527,222 shares of the stock traded hands, compared to its average volume of 1,746,685. Thermo Fisher Scientific Inc. has a 12-month low of $409.85 and a 12-month high of $627.88. The business has a 50-day moving average of $487.28 and a two-hundred day moving average of $526.70. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market capitalization of $159.13 billion, a PE ratio of 25.50, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.11 earnings per share. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.
Thermo Fisher Scientific Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were issued a $0.43 dividend. The ex-dividend date was Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.
Insider Buying and Selling
In related news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the sale, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the sale, the chief executive officer now owns 115,174 shares in the company, valued at approximately $59,506,950.58. This represents a 7.99 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock valued at $13,106,062 over the last 90 days. Insiders own 0.33% of the company's stock.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
